Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans

CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a lower effectiveness of the BNT162b2 vaccine in preventing the sequelae of SARS-CoV-2 infection compared with the mRNA-1273 vaccine could not be ruled out. These findings may help inform decision-making in future vaccination campaigns.PMID:35696161 | DOI:10.1001/jamainternmed.2022.2109

Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research